Doximity, Inc. (NASDAQ:DOCS) Shares Bought by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC lifted its position in shares of Doximity, Inc. (NASDAQ:DOCS) by 33.7% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 870,322 shares of the company’s stock after purchasing an additional 219,448 shares during the period. Los Angeles Capital Management LLC’s holdings in Doximity were worth $46,466,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in DOCS. FMR LLC increased its holdings in shares of Doximity by 30.5% during the 3rd quarter. FMR LLC now owns 6,837,733 shares of the company’s stock worth $297,920,000 after buying an additional 1,598,602 shares during the last quarter. Lord Abbett & CO. LLC acquired a new stake in Doximity in the 3rd quarter valued at $29,453,000. Wilmington Savings Fund Society FSB acquired a new stake in Doximity in the 3rd quarter valued at $24,691,000. Geode Capital Management LLC increased its holdings in Doximity by 19.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,856,984 shares of the company’s stock valued at $124,503,000 after purchasing an additional 472,565 shares in the last quarter. Finally, Retirement Systems of Alabama increased its holdings in Doximity by 254.3% in the 3rd quarter. Retirement Systems of Alabama now owns 534,256 shares of the company’s stock valued at $23,278,000 after purchasing an additional 383,480 shares in the last quarter. 87.19% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Timothy S. Cabral sold 20,000 shares of the business’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $57.62, for a total transaction of $1,152,400.00. Following the transaction, the director now owns 6,360 shares in the company, valued at approximately $366,463.20. The trade was a 75.87 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 37.40% of the company’s stock.

Doximity Stock Up 0.2 %

Shares of NASDAQ:DOCS opened at $72.49 on Tuesday. The firm has a market capitalization of $13.53 billion, a P/E ratio of 72.49, a price-to-earnings-growth ratio of 4.10 and a beta of 1.39. Doximity, Inc. has a 12-month low of $22.96 and a 12-month high of $85.21. The firm has a fifty day moving average of $60.57 and a two-hundred day moving average of $49.71.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Wells Fargo & Company reiterated an “equal weight” rating on shares of Doximity in a report on Friday, February 7th. JPMorgan Chase & Co. increased their price target on Doximity from $30.00 to $48.00 and gave the company a “neutral” rating in a report on Thursday, November 21st. Leerink Partnrs upgraded Doximity from a “hold” rating to a “strong-buy” rating in a report on Friday, February 7th. The Goldman Sachs Group upped their price objective on shares of Doximity from $58.00 to $80.00 and gave the company a “neutral” rating in a research report on Monday, February 10th. Finally, Bank of America upped their price objective on shares of Doximity from $54.00 to $57.00 and gave the company a “neutral” rating in a research report on Monday, January 6th. Eleven analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $64.22.

Doximity Profile

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.